CD4 and neoplasm: Analysis of lymphocytes (CD3+) revealed a significant increase in the percentage of CD4+ (p = 0.0079) among total tumor cells in the group treated with the SFV/IFNg compared to the PBS group, while percent of T-lymphocytes (CD3+) did not differ (Figure 8a,b).